<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005988</url>
  </required_header>
  <id_info>
    <org_study_id>99-205</org_study_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>GENE-C9909-38</secondary_id>
    <secondary_id>NCI-G00-1801</secondary_id>
    <secondary_id>CDR0000067977</secondary_id>
    <nct_id>NCT00005988</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy</brief_title>
  <official_title>A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bone marrow transplantation may be able to replace immune cells that were&#xD;
      destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the&#xD;
      transplanted cells can make an immune response against the body's normal tissues. Treatment&#xD;
      of the donor bone marrow with the patient's white blood cells and a monoclonal antibody may&#xD;
      prevent this from happening.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of bone marrow transplantation with&#xD;
      specially treated bone marrow in treating patients who have hematologic cancer that has not&#xD;
      responded to previous therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine if patients with refractory, high risk hematologic malignancies or&#xD;
      bone marrow failure who receive HLA haploidentical bone marrow treated with anti-B7 antibody&#xD;
      have normal engraftment. II. Determine if these patients are free of hyperacute graft versus&#xD;
      host disease (GVHD), defined as grade D GVHD in the first 10 posttransplant days, when&#xD;
      treated with this regimen. III. Determine if these patients have an acceptable incidence of&#xD;
      life threatening grade D GHVD in the first 50 posttransplant days following this treatment&#xD;
      regimen. IV. Determine the safety and tolerability of this treatment regimen in this patient&#xD;
      population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients undergo leukapheresis to collect white blood&#xD;
      cells which are incubated with donor bone marrow cells in the presence of anti-B7.1 and&#xD;
      anti-B7.2 antibodies for 36 hours. Patients receive total body irradiation twice daily on&#xD;
      days -6 to -3, cyclophosphamide IV daily on days -2 and -1, and methylprednisolone IV every&#xD;
      12 hours for a total of 4 doses on days -2 to 0. Patients are infused with the treated donor&#xD;
      bone marrow on day 0. Patients then receive methotrexate IV on days 1, 3, 6, and 11 and&#xD;
      leucovorin calcium IV 24 hours after each dose of methotrexate every 6 hours for 3-8 doses&#xD;
      each time. Patients also receive cyclosporine IV or orally twice daily on days -2 to 100.&#xD;
      Patients are followed every 2 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2000</start_date>
  <completion_date type="Actual">March 8, 2002</completion_date>
  <primary_completion_date type="Actual">June 16, 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>up to 30 days post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyperacute GVHD</measure>
    <time_frame>up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade D acute GVHD</measure>
    <time_frame>up to 50 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donor bone marrow will be harvested on Day -2&#xD;
Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.&#xD;
Bone marrow will be infused intravenously&#xD;
Cyclophosphamide will be administered IV once daily&#xD;
Total Body Irradiation (TBI) will be delivered per institutional practice&#xD;
Methylprednisolone will be administered IV as 4 doses separated by 12 hours,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated bone marrow transplantation</intervention_name>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>in vitro-treated bone marrow transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¤40 years.&#xD;
&#xD;
          -  Diagnoses-patients with the following hematologic malignancies and bone marrow failure&#xD;
             syndromes:&#xD;
&#xD;
               -  Acute myelogenous leukemia-induction failure, relapse, second or greater complete&#xD;
                  remission (CR)&#xD;
&#xD;
               -  Acute lymphocytic leukemia-induction failure, relapse, second or greater CR,&#xD;
                  first CR with t(9;22), t(8;14), or t(4;11)&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (intermediate or high grade) which has failed to achieve&#xD;
                  CR with at least two induction regimens, relapse, second or greater CR&#xD;
&#xD;
               -  Multiple myeloma with poor prognostic features (elevated 0-2 microglobulin or&#xD;
                  high labeling index)&#xD;
&#xD;
               -  Hodgkin's disease in relapse or which fails to achieve CR after two chemotherapy&#xD;
                  regimens&#xD;
&#xD;
               -  Congenital or acquired bone marrow failure - poorly responsive to or intolerant&#xD;
                  of current therapy&#xD;
&#xD;
               -  Myelodysplastic syndrome of all subtypes except refractory anemia (RA)&#xD;
&#xD;
          -  Patient has a haploidentical family member that meets medical criteria for donation.&#xD;
&#xD;
          -  Eligibility for other transplant types:&#xD;
&#xD;
               -  Patient considered likely to have clinical deterioration and rapid disease&#xD;
                  progression during an unrelated donor search, or&#xD;
&#xD;
               -  Patient who has already had an unproductive donor search or&#xD;
&#xD;
               -  Patient ineligible for or has refused autologous transplant&#xD;
&#xD;
          -  Adequate renal and hepatic function for age:&#xD;
&#xD;
               -  Serum creatinine &lt;2 x ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT, SGPT) x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST, SGOT) x ULN&#xD;
&#xD;
               -  Total bilirubin 5_2 x ULN except if bilirubin is elevated due to Gilbert's&#xD;
                  syndrome or hemolytic anemia&#xD;
&#xD;
          -  Adequate cardiac and pulmonary function for age.&#xD;
&#xD;
          -  ECOG Performance Status 0, 1, or 2 or Lansky performance scale &gt;50% for patients &lt;16&#xD;
             years of age.&#xD;
&#xD;
          -  Voluntary witnessed written informed consent. Children will be asked for assent where&#xD;
             appropriate.&#xD;
&#xD;
          -  The patient, if female, must be post-menopausal, premenarcheal, or sterile, or if the&#xD;
             patient is of childbearing potential, she must be practicing a method of birth control&#xD;
             considered effective and medically acceptable by the investigator for a minimum of 1&#xD;
             month prior to study entry and at least 2 months after the study end.&#xD;
&#xD;
          -  Patient must have undergone successful leukapheresis to obtain adequate antigen&#xD;
             presenting cells.&#xD;
&#xD;
          -  Any patient who enters the study in a relapse state, with evidence of end organ&#xD;
             (pulmonary, renal, or hepatic) toxicity, or with recent recovery from infection, who&#xD;
             may potentially have little benefit from this protocol, must have his/her eligibility&#xD;
             status discussed with the Principal Investigator.&#xD;
&#xD;
          -  Patient must have life expectancy of at least 12 weeks.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Eligibility for other transplant types:&#xD;
&#xD;
               -  Patient has family donor who is matched or single antigen mismatched at HLA-A,&#xD;
                  HLA-B, HLA-DR, and HLA-DQ. Donorrecipient matching must be evaluated via both&#xD;
                  phenotype and genotype.&#xD;
&#xD;
               -  Patient has available unrelated donor who is matched at HLA-A, HLA-B, and HLA-DR.&#xD;
                  Donor-recipient matching must be evaluated via both phenotype and genotype.&#xD;
&#xD;
          -  Active uncontrolled infection (continued positive blood or soft tissue cultures&#xD;
             despite appropriate antibiotic treatment)&#xD;
&#xD;
          -  Positive 13-HCG in a female of childbearing potential&#xD;
&#xD;
          -  Evidence of HIV infection or known HIV positive serology&#xD;
&#xD;
          -  Any prior bone marrow transplant&#xD;
&#xD;
          -  A peripheral blood differential count at the time of leukapheresis with greater than&#xD;
             25% blasts. This exclusion criterion is valid only for the first four patients&#xD;
             enrolled.&#xD;
&#xD;
          -  Patients with Fanconi's anemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Guinan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood. 2008 Sep 15;112(6):2232-41. doi: 10.1182/blood-2008-03-143636. Epub 2008 Jul 10.</citation>
    <PMID>18617635</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>April 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2004</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Eva C. Guinan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

